Matsuyama Wataru, Suetsugu Takayuki, Kawabata Takashi, Kubota Shingo, Iwakawa Jun, Higashimoto Ikkou, Osame Mitsuhiro, Arimura Kimiyoshi
Division of Respiratory Medicine, Respiratory and Stress Care Center, Kagoshima University Hospital.
Nihon Kokyuki Gakkai Zasshi. 2007 Feb;45(2):194-7.
It is well known that lung cancer patients with severe chronic obstructive pulmonary disease (COPD) have a higher risk of postoperative complications than patients without COPD. However, the information regarding preoperative treatment to improve pulmonary function of the lung cancer patients with severe COPD is limited. Here, we report 3 lung cancer cases with severe COPD. Although all patients received medication without tiotropium bromide in combination with pulmonary rehabilitation for 1 or 2 months, their pulmonary function did not improve and the predicted postoperative FEV1/predicted FEV1 was below 40% in all cases. After the approval in Japan for use of tiotropium bromide in the treatment of COPD, all patients were treated with tiotropium bromide. The pulmonary function in all patients improved 2-4 weeks after the start of tiotropium bromide, and we performed lobectomy safely. Currently all patients maintain good pulmonary function without recurrence of lung cancer. We propose that treatment of tiotropium bromide might be one of the effective preoperative methods to improve pulmonary function of lung cancer patients with severe COPD.
众所周知,患有严重慢性阻塞性肺疾病(COPD)的肺癌患者比没有COPD的患者术后并发症风险更高。然而,关于改善患有严重COPD的肺癌患者肺功能的术前治疗的信息有限。在此,我们报告3例患有严重COPD的肺癌病例。尽管所有患者均接受了不联合噻托溴铵的药物治疗并进行了1或2个月的肺康复,但他们的肺功能并未改善,且所有病例中预计术后第1秒用力呼气量(FEV1)/预计FEV1均低于40%。在日本批准噻托溴铵用于治疗COPD后,所有患者均接受了噻托溴铵治疗。所有患者在开始使用噻托溴铵2 - 4周后肺功能得到改善,并且我们安全地进行了肺叶切除术。目前所有患者均保持良好的肺功能,肺癌无复发。我们认为噻托溴铵治疗可能是改善患有严重COPD的肺癌患者肺功能的有效术前方法之一。